Novo Nordisk's phase 1/2 study of amycretin, a next-generation obesity amylin analogue, demonstrated substantial weight loss exceeding 24% at the highest dose after 36 weeks. However, weight reductions overlapped across tested doses, and side effect rates were high, raising questions about optimal dosing strategies. Published in The Lancet and presented at ADA, the findings spotlight amycretin’s efficacy while highlighting the need for dose determination to maximize therapeutic benefit and safety.